Home

Introduction

Statistics

Authorized Vaccines

Phase III Vaccines

Phase II Vaccines

Phase I Vaccines

Preclinical Vaccines

Vaccine Safety

Vaccine Design

Literature Search

News

Data Submission

Data Exchange

Data Download

Tutorial

Links

Documentation

Updates

Acknowledgements

FAQs

Disclaimer

Contact Us

Phase III COVID-19 Vaccines

This site presents an alphabetically-ordered list of COVID-19 vaccines that are currently in Phase III clinical trials as of July 23, 2022.

Contents:

1. AG0302-COVID19
2. ARCoV
3. ARCT-154
4. AZD2816
5. BBV154
6. COVI-VAC
7. COVID-19 subunit vaccine by HIPRA
8. COVID-19 subunit vaccine by PT Bio Farma
9. DelNS1-2019-nCoV-RBD-OPT1
10. DS-5670a
11. GEMCOVAC-19
12. GRAd-CoV2
13. GX-19
14. IIBR-100
15. INO-4800
16. KD-414
17. LVRNA009
18. LYB001
19. mRNA-1273.211
20. mRNA-1273.214
21. mRNA-1273.529
22. Nanocovax
23. NDV-HXP-S
24. Omicron COVID-19 inactivated vaccine by China National Biotec Group Company Limited
25. PIKA Recombinant COVID-19 Vaccine
26. Recombinant SARS-CoV-2 vaccine (Sf9 cell)
27. ReCOV
28. S-268019
29. SCB-2019
30. SCTV01C
31. UB-612
32. V-01
33. VAT00002

1. AG0302-COVID19
• Clinical trial ID:
• Phase II/III: NCT04655625
• Age subgroups: 18 years and above
• Location: Japan
• Type: DNA vaccine
• Manufacturer: AnGes, Inc.
• VIOLIN: 5882
• VO: VO_0005322
2. ARCoV
• Clinical trial ID:
• Phase III: NCT04847102
• Age subgroups: 18 years and above
• Location: China
• Phase II: ChiCTR2100041855
• Age subgroups: 18-59 years
• Location: China
• Phase I: ChiCTR2000034112
• Age subgroups: 18-59 years, 60 years and above
• Location: China
• Phase I: ChiCTR2000039212
• Age subgroups: 18-59 years
• Location: China
• Type: mRNA vaccine
• Manufacturer: Academy of Military Sciences, Walvax Biotech.
• Publications:
• Zhang et al. A Thermostable mRNA Vaccine against COVID-19. Cell. 2020; 182(5); 1271-1283. [PubMed: 32795413].
• VIOLIN: 5783
• VO: VO_0005161
3. ARCT-154
• Clinical trial ID:
• Phase III: ISRCTN15779782
• Age subgroups: 16 years and above
• Location: Switzerland
• Phase II/III: NCT05012943
• Age subgroups: 18 years and above
• Location: Unknown
• Type: RNA vaccine
• Manufacturer: Arcturus Therapeutics, Inc.
• VIOLIN: 5884
• VO: VO_0005331
4. AZD2816
• Clinical trial ID:
• Phase II/III: NCT04973449
• Age subgroups: 18 years and above
• Location: Brazil, UK
• Type: Recombinant vector vaccine
• Manufacturer: AstraZeneca, University of Oxford
• VIOLIN: 5881
• VO: VO_0005319
5. BBV154
• Clinical trial ID:
• Phase I: NCT04751682
• Age subgroups: 18-60 years
• Location: India
• Type: Recombinant vector vaccine
• Manufacturer: Bharat Biotech International Limited
• VIOLIN: 5839
• VO: VO_0005174
6. COVI-VAC
• Clinical trial ID:
• Phase III: ISRCTN15779782
• Age subgroups: 16 years and above
• Location: Switzerland
• Phase I: NCT04619628
• Age subgroups: 18-30 years
• Location: UK
• Type: Live, attenuated vaccine
• Manufacturer: Codagenix, Inc.
• VIOLIN: 5824
• VO: VO_0005187
7. COVID-19 subunit vaccine by HIPRA
• Clinical trial ID:
• Phase III: NCT05246137
• Age subgroups: 16 years and above
• Location: Italy, Portugal, Spain
• Phase III: NCT05303402
• Age subgroups: 18 years and above
• Location: Spain, Turkey
• Phase II: EUCTR2021-005226-26-ES
• Age subgroups: 18-64 years, 65 years and above
• Location: Spain
• Phase I/II: NCT05007509
• Age subgroups: 18-39 years
• Location: Spain
• Type: Subunit vaccine
• Manufacturer: Laboratorios Hipra, S.A.
• VIOLIN: 5883
• VO: VO_0005321
8. COVID-19 subunit vaccine by PT Bio Farma
• Clinical trial ID:
• Phase III: NCT05433285
• Age subgroups: 18 years and above
• Location: Indonesia
• Phase II/III: NCT05313035
• Age subgroups: 18 years and above
• Location: Indonesia
• Phase I/II: NCT05067894
• Age subgroups: 18-59 years, 60 years and above
• Location: Indonesia
• Type: Subunit vaccine
• Manufacturer: PT Bio Farma
• VIOLIN: 5895
• VO: VO_0005343
9. DelNS1-2019-nCoV-RBD-OPT1
• Clinical trial ID:
• Phase III: ChiCTR2100051391
• Age subgroups: 18 years and above
• Location: China
cv
• Phase II: ChiCTR2000039715
• Age subgroups: 18 years and above
• Location: China
• Type: Recombinant vector vaccine
• Manufacturer: University of Hong Kong, Xiamen University, Beijing Wantai Biological Pharmacy
• VIOLIN: 5806
• VO: VO_0005087
10. DS-5670a
• Clinical trial ID:
• Phase I/II/III: jRCT2071210106
• Age subgroups: 18-64 years, 65 years and above
• Location: Japan
• Phase I/II: NCT04821674
• Age subgroups: 20-64 years, 65-74 years
• Location: Japan
• Type: mRNA vaccine
• Manufacturer: Daiichi Sankyo Co., Ltd.
• VIOLIN: 5854
• VO: VO_0005245
11. GEMCOVAC-19
• Clinical trial ID:
• Phase II/III: CTRI/2022/04/041880
• Age subgroups: 5-17 years
• Location: India
• Type: mRNA vaccine
• Manufacturer: Gennova Biopharmaceuticals Limited
• VIOLIN: 5933
• VO: VO_0005413
12. GRAd-CoV2
• Clinical trial ID:
• Phase II/III: NCT04791423
• Age subgroups: 18-64 years, 65 years and older
• Location: Italy
• Phase I: NCT04528641
• Age subgroups: 18-55 years, 65-85 years
• Location: Italy
• Type: Recombinant vector vaccine
• Manufacturer: ReiThera, Leukocare, Univercells
• VIOLIN: 5787
• VO: VO_0005169
13. GX-19
• Clinical trial ID:
• Phase II/III: NCT05067946
• Age subgroups: 18 years and above
• Location: South Korea
• Phase I/II: NCT04715997
• Age subgroups: 18-55 years
• Location: South Korea
• Phase I/II: NCT04445389
• Age subgroups: 18-50 years
• Location: South Korea
• Type: DNA vaccine
• Manufacturer: Genexine
• VIOLIN: 5788
• VO: VO_0005170
14. IIBR-100
• Other names: BriLife
• Clinical trial ID:
• Phase II/III: NCT04990466
• Age subgroups: 18-85 years
• Location: Unknown
• Phase I/II: NCT04608305
• Age subgroups:
• Phase I: 18-55 years
• Phase II: 18-55 years, 56-85 years
• Location: Israel
• Type: Recombinant vector vaccine
• Manufacturer: Israel Institute for Biological Research, Weizmann Institute of Science
• VIOLIN: 5799
• VO: VO_0005090
15. INO-4800
• Clinical trial ID:
• Phase II/III: NCT04642638
• Age subgroups:
• Phase II: 18-50 years, 51-64 years, 65 years and above
• Phase III: 18 years and above
• Location: USA
• Phase III: ISRCTN15779782
• Age subgroups: 16 years and above
• Location: Switzerland
• Type: DNA vaccine
• Manufacturer: Inovio Pharmaceuticals
• Publications:
• Tebas et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine. 2020; 100689; . [PubMed: 33392485].
• Smith et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020; 11(1); 2601. [PubMed: 32433465].
• VIOLIN: 5793
• VO: VO_0005172
16. KD-414
• Clinical trial ID:
• Phase II/III: jRCT2071210081
• Age subgroups: 18 years and above
• Location: Japan
• Phase I/II: jRCT2071200106
• Age subgroups: 20-64 years, 65 years and above
• Location: Japan
• Type: Inactivated or "killed" vaccine
• Manufacturer: KM Biologics Co., Ltd.
• VIOLIN: 5859
• VO: VO_0005250
17. LVRNA009
• Clinical trial ID:
• Phase III: NCT05428592
• Age subgroups: 18 years and above
• Location: Pakistan
• Type: mRNA vaccine
• Manufacturer: AIM Vaccine Co., Ltd.
• VIOLIN: 5925
• VO: VO_0005414
18. LYB001
• Clinical trial ID:
• Phase II/III: NCT05137444
• Age subgroups: 18-59 years, 60 years and above
• Location: Unknown
• Type: Virus-like particle
• Manufacturer: Yantai Patronus Biotech Co., Ltd.
• VIOLIN: 5901
• VO: VO_0005348
19. mRNA-1273.211
• Clinical trial ID:
• Phase II/III: NCT04927065
• Age subgroups: 18 years and above
• Location: USA
• Type: mRNA vaccine
• Manufacturer: Moderna
• VIOLIN: 5876
• VO: VO_0005277
20. mRNA-1273.214
• Clinical trial ID:
• Phase III: NCT05436834
• Age subgroups: 6 months-5 years
• Location: USA
• Type: mRNA vaccine
• Manufacturer: Moderna
• VIOLIN: 5939
• VO: VO_0005415
21. mRNA-1273.529
• Clinical trial ID:
• Phase II/III: NCT05249829
• Age subgroups: 16 years and above
• Location: United Kingdom
• Type: mRNA vaccine
• Manufacturer: Moderna
• VIOLIN: 5926
• VO: VO_0005416
22. Nanocovax
• Clinical trial ID:
• Phase III: NCT04922788
• Age subgroups: 18-45 years, 45-60 years, and 61 years and above
• Location: Vietnam
• Phase I/II: NCT04683484
• Age subgroups:
• Phase I: 18-50 years
• Phase II: 12-75 years
• Location: Vietnam
• Type: Subunit vaccine
• Manufacturer: Nanogen Pharmaceutical Biotechnology
• VIOLIN: 5809
• VO: VO_0005092
23. NDV-HXP-S
• Clinical trial ID:
• Phase II/III: NCT05354024
• Age subgroups: 18-59 years, 60 years and above
• Location: Brazil
• Phase I/II: NCT04764422
• Age subgroups:
• Phase I: 18-59 years
• Phase II: 18-75 years
• Location: Thailand
• Type: Recombinant vector vaccine
• Manufacturer: Icahn School of Medicine at Mount Sinai, Mahidol University
• Publications:
• Sun et al. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine. 2020; 62; 103132. [PubMed: 33232870].
• VIOLIN: 5841
• VO: VO_0005235
24. Omicron COVID-19 inactivated vaccine by China National Biotec Group Company Limited
• Clinical trial ID:
• Phase III: NCT05374954
• Age subgroups: 18-59 years, 60 years and above
• Location: China
• Type: Inactivated or "killed" vaccine
• Manufacturer: China National Biotec Group Company Limited
• VIOLIN: 5940
• VO: VO_0005417
25. PIKA Recombinant COVID-19 Vaccine
• Clinical trial ID:
• Phase II/III: NCT05463419
• Age subgroups: 18 years and above
• Location: Unknown
• Phase I: ACTRN12621001009808
• Age subgroups: 18-65 years
• Location: New Zealand
• Type: Subunit vaccine
• Manufacturer: Yisheng Biopharma
• VIOLIN: 5892
• VO: VO_0005345
26. Recombinant SARS-CoV-2 vaccine (Sf9 cell)
• Clinical trial ID:
• Phase III: NCT04904471
• Age subgroups: 18 years and above
• Location: China
• Phase III: NCT04887207
• Age subgroups: 18 years and above
• Location: China
• Phase II: NCT04718467
• Age subgroups: 18-59 years, 60 years and above
• Location: China
• Type: Subunit vaccine
• Manufacturer: West China Hospital, Sichuan University
• Publications:
• Meng et al. Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Signal Transduct Target Ther. 2021; 6(1); 271. [PubMed: 34267185].
• VIOLIN: 5812
• VO: VO_0005095
27. ReCOV
• Clinical trial ID:
• Phase II/III: NCT05084989
• Age subgroups: 18-59 years, 60 years and above
• Location: Unknown
• Phase I: NCT04818801
• Age subgroups: 18-55 years, 56-80 years
• Location: New Zealand
• Type: Subunit vaccine
• Manufacturer: Jiangsu Rec-Biotechnology
• VIOLIN: 5863
• VO: VO_0005252
28. S-268019
• Clinical trial ID:
• Phase III: jRCT2031210613
• Age subgroups: 20 years and above
• Location: Japan
• Phase III: NCT05212948
• Age subgroups: 18 years and above
• Location: Vietnam
• Phase I/II: jRCT2051200092
• Age subgroups: 20-64 years
• Location: Japan
• Type: Subunit vaccine
• Manufacturer: Shionogi
• VIOLIN: 5813
• VO: VO_0005096
29. SCB-2019
• Clinical trial ID:
• Phase III: NCT05012787
• Age subgroups: 18 years and above
• Location: South Africa, Ukraine
• Phase II/III: NCT04672395
• Age subgroups: 18 years and above
• Location: Belgium, Brazil, Colombia, Dominican Republic, Germany, Nepal, Panama, Philippines, Poland, South Africa
• Type: Subunit vaccine
• Manufacturer: Clover Biopharmaceuticals, GSK, Dynavax
• Publications:
• Richmond et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021; S0140-6736(21)00241-5; . [PubMed: 33524311].
• VIOLIN: 5797
• VO: VO_0004994
30. SCTV01C
• Clinical trial ID:
• Phase II/III: NCT05043285
• Age subgroups: 18 years and above
• Location: China
• Phase II/III: NCT05043311
• Age subgroups: 18 years and above
• Location: China
• Type: Subunit vaccine
• Manufacturer: Sinocelltech Ltd.
• VIOLIN: 5890
• VO: VO_0005337
31. UB-612
• Clinical trial ID:
• Phase II/III: NCT04683224
• Age subgroups: 18-59 years, 60 years and above
• Type: Subunit vaccine
• Manufacturer: Vaxxinity
• VIOLIN: 5798
• VO: VO_0004995
32. V-01
• Clinical trial ID:
• Phase III: NCT05096845
• Age subgroups: 18-59 years, 60 years and above
• Location: Philippines
• Phase III: NCT05096832
• Age subgroups: 18-59 years, 60 years and above
• Location: Pakistan
• Phase II: ChiCTR2100045107
• Age subgroups: 18-59 years, 60-69 years, 70 years and above
• Location: China
• Type: Subunit vaccine
• Manufacturer: Livzon Mabpharm Inc.
• VIOLIN: 5856
• VO: VO_0005247
33. VAT00002
• Other names: VAT00008, CoV2 preS dTM
• Clinical trial ID:
• Phase III: NCT05405283
• Age subgroups: 60 years and above
• Location: France
• Phase III: NCT04904549
• Age subgroups: 18 years and above
• Location: USA, Colombia, Honduras, Japan
• Phase III: PACTR202011523101903
• Age subgroups: 18-44 years, 45-64 years, 65 years and above
• Location: Kenya
• Phase II: NCT04762680
• Age subgroups: 18 years and above
• Location: USA
• Phase I/II: NCT04537208
• Age subgroups: 18-49 years, 50 years and above
• Location: USA
• Type: Subunit vaccine
• Manufacturer: Sanofi Pasteur, GSK
• Publications:
• Goepfert et al. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study. Lancet. 2021; 21(9); 1257-1270. [PubMed: 33887209].
• VIOLIN: 5833
• VO: VO_0005085

Provenance: All data in Cov19VaxKB originates from manual curation of various resources, including the WHO's COVID-19 Vaccine Tracker.

Note: The page was updated on July 23, 2022. Please provide us with any new information that you believe would be useful if included on the website.